Great day for lung cancer care! Addition of just 3 cycles of nivolumab immunotherapy to standard neoadjuvant chemo leads to improved overall survival for surgically resectable lung cancer! #LCSM
Well done @michaelconroy on a superb poster presentation at #SITC24 on our work exploring how longitudinal changes in the gut microbiome impact outcomes from neoadjuvant IO in several prospective NSCLC trials @HopkinsThoracic
Thanks @lcfamerica@IASLC for funding this work #LCSM
This is HOPE. Patient #2 in the Peptide vaccine ALK + NSCLC clinical trial! We are hopeful this groundbreaking vaccine will turn this terminal disease into a chronic one. I believe in my doctor as much as he believes in me. @ALKPositiveinc@oncodaily@OncogeneCancer@OncoAlert
Dr. @jennifermarksmd breaks down latest data for Trastuzumab Deruxtecan in HER2-overexpressing solid tumors including NSCLC at #LungCancerSymposium. Rapidly evolving space & need more prospective data to ID pts most likely to respond such as concurrent HER2 amp. @LombardiCancer